News Search Results
Jul 15, 2026, 10:15 ET Angle Seat Valve Market worth $0.53 billion by 2032 - Exclusive Report by MarketsandMarkets™
performance in high-cycle industrial applications. These valves are widely used across industries such as food & beverages, pharmaceutical & biotechnology, chemical processing, semiconductors, and water & wastewater treatment, where automated and reliable fluid control is essential. Their ability
More news about: MarketsandMarkets
Jul 15, 2026, 10:01 ET NLP in Healthcare & Life Sciences Market worth $30.06 billion by 2031 - Report by MarketsandMarkets™
organizations increasingly adopt AI to automate clinical, administrative, and research workflows. Healthcare providers, payers, pharmaceutical companies, biotechnology firms, and research organizations are leveraging NLP to extract insights from unstructured data such as electronic health records (EHRs), physician
More news about: MarketsandMarkets
Jul 15, 2026, 09:56 ET Locus FS Expands The Woodlands Laboratory to Advance Biosurfactant Innovation
[email protected] LOCUS FSLocus Fermentation Solutions (Locus FS) is a USA-based biotechnology company delivering high-performance specialty chemical formulations enhanced with novel glycolipids and microbial blends. Built on deep microbial
More news about: Locus FS
Jul 15, 2026, 09:24 ET Decoy Therapeutics Stockholders Elect Patricia Gauthier to Board of Directors
CAMBRIDGE, Mass., July 15, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms, today announced
More news about: Decoy Therapeutics, Inc
Jul 15, 2026, 09:00 ET Bambusa Therapeutics Appoints Howard Liang, Ph.D. to its Board of Directors and Establishes Scientific Advisory Board
Directors, along with the formation of the company's Scientific Advisory Board. Dr. Liang is an accomplished biotechnology executive with more than three decades of leadership experience spanning biotechnology management, financing, strategy, and research at leading biopharmaceutical companies and top-tier investment
More news about: Bambusa Therapeutics
Jul 15, 2026, 09:00 ET HighVista Appoints Ramit Malhotra as Principal on GP-Led Secondaries Team
span private markets, including private credit, lower middle market private equity, and early-stage venture capital; public markets, including biotechnology equities and hedged public markets strategies; as well as multi-asset alternatives.Important DisclosureThe views and opinions
More news about: HighVista Strategies LLC
Jul 15, 2026, 08:02 ET Lakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel
Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class,
More news about: Lakewood-Amedex Biotherapeutics Inc.
Jul 15, 2026, 08:00 ET Kalohexis Presents Data Demonstrating Dual MC3R/MC4R Activation Drives Weight Loss, Limits Rebound, and Preserves Lean Mass in Obese Nonhuman Primates at ICO 2026
NORTHBROOK, Ill., July 15, 2026 /PRNewswire/ -- Kalohexis, Inc., a clinical-stage biotechnology company harnessing the melanocortin system to shape the next era of metabolic disease care starting with obesity and cancer cachexia, today announced
More news about: Kalohexis
Jul 15, 2026, 07:45 ET Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)
Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system
More news about: Intensity Therapeutics Inc.
Jul 15, 2026, 06:00 ET HERVolution Therapeutics Presents Clinical Evidence of HERV-K Driving Metabolic Senescence at the International Congress on Obesity 2026
, Denmark and NEW YORK, July 15, 2026 /PRNewswire/ -- HERVolution Therapeutics ApS, a biotechnology company pioneering human endogenous retrovirus (HERV)-targeting immunotherapies for oncology, metabolic diseases, and longevity, today announced
More news about: HERVolution Therapeutics
Jul 15, 2026, 06:00 ET Ascletis Selects for Clinical Development a Fixed-Dose Combination of First-in-Class Oral Small Molecule GIPR Agonist, ASC48, and Oral Small Molecule GLP-1R Agonist, ASC30
loss and tolerability as tirzepatide weekly injections."About Ascletis Pharma Inc.Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potentially best-in-class and first-in-class therapeutics to treat metabolic diseases.
More news about: Ascletis Pharma Inc.
Jul 14, 2026, 22:58 ET Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants
WALTHAM, Mass., July 14, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB), ("Q32 Bio") a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today announced the pricing
More news about: Q32 Bio
Jul 14, 2026, 21:09 ET GEM and Senhwa Biosciences have formally executed a Share Purchase Agreement for up to NT$500 million
conditions of the SPA. During the lifetime of the SPA, GEM will not, directly or indirectly, effect any short sale of Senhwa's shares.Taiwan's biotechnology industry continues to attract increasing international attention through innovative oncology research, expanding global clinical collaborations
More news about: Senhwa Biosciences, Inc
Jul 14, 2026, 20:00 ET Insilico Medicine and Bora Pharmaceuticals Announce Strategic Alliance for AI-Driven Drug Discovery and Development
toward demonstrating how AI-discovered medicines can be developed faster, more efficiently, and with greater scalability."As an AI-native biotechnology company, Insilico is redefining the efficiency of preclinical drug development through its advanced AI and automation platform. While traditional
More news about: Insilico Medicine
Jul 14, 2026, 15:25 ET The Inner Circle acknowledges Linda J Kenney as a Pinnacle Professional Member Inner Circle of Excellence
Circle of Excellence for her contributions to Mechanobiology and Therapeutic Ultrasound. Linda J. Kenney has built a distinguished career in biotechnology and life sciences, recognized for her leadership in advancing mechanobiology research and developing innovative therapeutic applications. As president
More news about: The Inner Circle
Jul 14, 2026, 13:16 ET Jones Walker Grows M&A and Private Equity Team with Addition of Former Walker Eisenbraun Attorneys, Names Head of Texas Offices
a broad range of industries, including software, optical, networking, ecommerce, semiconductor production, telecommunications, medical devices, biotechnology, manufacturing, defense, aviation, and real estate investment trusts.About Jill BrumbergerJill is a veteran corporate and transactional
More news about: Jones Walker LLP
Jul 14, 2026, 12:00 ET ACROBiosystems Obtains PMDA Material Suitability Confirmation for GMP-grade IL-15, Ensuring Reliable Quality and Strengthening the Biopharmaceutical Approval Process
biopharmaceutical approval process.About ACROBiosystems Group：ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and healthcare industries by providing innovative products and business models.
More news about: ACROBiosystems Group
Jul 14, 2026, 11:27 ET NABR: The U.S. Fish and Wildlife Service for the Second Time Rejects Activists' Petition to List Long-Tailed Macaque Monkeys Under the Endangered Species Act
research, education, and testing. Members include more than 280 universities, medical and veterinary schools, teaching hospitals, pharmaceutical and biotechnology companies, patient groups, and academic and professional societies who rely on humane and responsible animal research to advance global human and
More news about: National Association for Biomedical Research
Jul 14, 2026, 11:15 ET LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
LinkedIn.About BiogenFounded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients' lives and to create value for shareholders and our communities.
More news about: Eisai Inc.
Jul 14, 2026, 10:57 ET Renew Labs Receives Accreditation from the College of American Pathologists
quality is the foundation behind the services, technologies, and programs we are advancing through Renew's platforms."Renew proudly supports biotechnology, biopharma, clinical research, and translational teams working to move complex molecular applications from discovery toward clinical implementation.
More news about: Renew Biotechnologies
Jul 14, 2026, 10:57 ET NABR: The U.S. Fish and Wildlife Service for the Second Time Rejects Activists' Petition to List Long-Tailed Macaque Monkeys Under the Endangered Species Act
research, education, and testing. Members include more than 280 universities, medical and veterinary schools, teaching hospitals, pharmaceutical and biotechnology companies, patient groups, and academic and professional societies who rely on humane and responsible animal research to advance global human and
More news about: National Association for Biomedical Research
Jul 14, 2026, 10:10 ET Biotech Visionary John F. Crowley to Keynote Emily Whitehead Foundation's 2026 Believe Ball in Philadelphia
Crowley, a biotech visionary whose race to save his children inspired the film Extraordinary Measures and the current president and CEO of the Biotechnology Innovation Organization (BIO), will keynote the Foundation's 2026 Believe Ball on Friday, Sept. 25.
More news about: Emily Whitehead Foundation
Jul 14, 2026, 10:00 ET QuantiPath Sponsors Tuskegee University Post-Doctoral Researcher to Advance Next-Generation Food Safety Science
QuantiPath, a biotechnology company revolutionizing food safety testing through precision genetic diagnostics, is proud to announce its sponsorship of Rejoice Nyarku, a post-doctoral
More news about: QuantiPath
Jul 14, 2026, 09:30 ET HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction
technical services, project out-licensing and product sales, the Company has forged extensive collaborations with a broad range of pharmaceutical and biotechnology companies, chemical firms, foundations, and research institutions. As of the end of 2025, it has empowered over 600 clients globally and contributed
More news about: HitGen Inc.
Jul 14, 2026, 08:47 ET Laboratory Operations and Technology Innovator Chris Clendening Joins Precision for Medicine to Lead Specialty Labs
laboratory strategy, operations and commercial growth across complex clinical trial environments. He most recently served as Senior Vice President of Biotechnology Operations and Product Development at Clario. Prior to Clario, Clendening spent more than a decade in executive leadership roles at PPD Central
More news about: PRECISION FOR MEDICINE